As of Feb 05
| -0.75 / -2.24%|
The 10 analysts offering 12-month price forecasts for Haemonetics Corp have a median target of 35.00, with a high estimate of 44.00 and a low estimate of 29.00. The median estimate represents a +6.81% increase from the last price of 32.77.
The current consensus among 12 polled investment analysts is to Hold stock in Haemonetics Corp. This rating has held steady since February, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.